30-day average of 20 articles ยท scale โ100 to +100
Across 20 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of AbbVie news is Bullish (+51)
on a scale from โ100 to +100.
That is about the same as the previous 30 days (+53).
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
Bullish +62
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AI-generated analysis
Key insights
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
๐ Bullish signals
๐AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
๐Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
๐ง The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
๐ฐTotal company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
๐ Risk factors
๐Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
โ ๏ธThe acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
๐AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Article
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
๐ง Neuroscience portfolio grew 20.3% to $3.23B in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
โ ๏ธ Acquisition expected to dilute 2026 adjusted EPS by $0.14 per share.
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
Bullish Signals
Shares surged 23% year-to-date, outperforming the market's 13% gain.
Skyrizi and Rinvoq revenue grew 15.1% to $8.79 billion.
Neuroscience revenue rose 20.3% to $3.23 billion in Q2.
Total revenue increased 10.2% to $16.99 billion with EPS up 22.9%.
Risk Factors
Humira revenue fell 35.9% to $756 million in Q2.
Apogee deal dilutes 2026 EPS by $0.72 per share.
Trailing P/E of 75x exceeds forward P/E of 16.4x.
Bullish Signals
AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
Total company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
Risk Factors
Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
The acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Company updateEarnings reportAI-generated analysis
AbbVie Inc. (NYSE: ABBV) and Merck & Co., Inc. (NYSE: MRK) are being compared as healthcare investment options, with AbbVie trading at a modest premium of 16.39x forward earnings versus Merck's 15.29x. The analysis highlights that while both companies face the challenge of sustaining earnings as their blockbuster drugs face competition, they are at different stages of this transition.
AbbVie demonstrated strong second-quarter performance with revenue increasing 10.2% to $16.99 billion and adjusted EPS climbing 22.9% to $3.65. This growth is driven by its immunology portfolio, specifically Skyrizi and Rinvoq, which generated approximately $8.03 billion in combined quarterly revenue. These figures represent a significant portion of total sales, indicating that AbbVie is successfully generating replacement revenue as Humira sales decline.
Merck reported more moderate growth with worldwide sales increasing 5% to $16.6 billion, led by Keytruda and Keytruda Qlex which generated about $8.4 billion. While Merck shows promising growth in Winrevair (up 75%) and Animal Health, its emerging portfolio is currently small relative to its oncology franchise. The article concludes that AbbVie offers greater visibility into an advancing growth transition, whereas Merck's investment case relies heavily on the future success of its next-generation medicines to offset potential Keytruda competition.
๐ AbbVie trades at a modest premium with strong Q2 revenue growth of 10.2%.
๐ฐ Adjusted EPS rose 22.9% driven by Skyrizi and Rinvoq sales.
๐ Global Skyrizi net revenue increased 24.4% while Rinvoq grew 24.5%.
๐ AbbVie offers greater visibility into its commercial transition than competitors.
๐ AbbVie trades at a forward P/E of 16.39x compared to Merck's 15.29x, representing a modest premium despite higher recent revenue growth.
๐ฐ AbbVie reported Q2 revenue of $16.99 billion (up 10.2%) and adjusted EPS of $3.65 (up 22.9%).
๐งฌ Skyrizi and Rinvoq combined generated $8.03 billion in quarterly revenue for AbbVie, driving its immunology growth.
๐ Global Skyrizi net revenue increased 24.4% while Rinvoq grew 24.5% on a reported basis.
๐ Merck's Q2 worldwide sales rose 5% to $16.6 billion, with Keytruda and Keytruda Qlex contributing $8.4 billion.
๐ Merck's Winrevair revenue surged 75% to $588 million, though it remains a small fraction of total sales compared to Keytruda.
โ ๏ธ AbbVie faces concentration risk as Skyrizi and Rinvoq combined contribute nearly half of its quarterly revenue.
๐ฎ Merck must build additional revenue to offset potential future pressure on Keytruda as U.S. exclusivity approaches in 2028.
๐ The article concludes AbbVie offers greater visibility into an established commercial transition compared to Merck's uncertain future portfolio expansion.
Bullish Signals
Revenue rose 10.2% to $16.99B with adjusted EPS up 22.9% to $3.65.
Skyrizi and Rinvoq generated $8.03B combined revenue as Humira declines.
Risk Factors
Revenue relies heavily on Skyrizi and Rinvoq sales.
Slower immunology growth threatens earnings and valuation.
Bullish Signals
AbbVie demonstrated strong second-quarter performance with revenue increasing 10.2% to $16.99 billion and adjusted EPS climbing 22.9% to $3.65.
The company's immunology medicines, Skyrizi and Rinvoq, generated approximately $8.03 billion in combined quarterly revenue, representing substantial replacement revenue as Humira sales decline.
Global Skyrizi net revenue increased 24.4% on a reported basis while Rinvoq grew 24.5%, indicating successful expansion of its core growth drivers.
Risk Factors
The combined contribution of Skyrizi and Rinvoq represents nearly half of AbbVie's quarterly revenue, creating substantial dependence on continued immunology growth.
Any meaningful slowdown in the growth of Skyrizi or Rinvoq would challenge the earnings expectations supporting AbbVie's current valuation premium.
AbbVie (ABBV) shares have surged 38.4% over the past twelve months, trading near their yearly highs despite a high valuation of 49.8x trailing earnings. Management identified a specific headwind beginning in 2027: the Inflation Reduction Act (IRA) price cap on its psychiatry drug Vraylar. This potential revenue pressure follows a similar impact seen with cancer drug Imbruvica, which faced significant sales declines attributed to IRA pricing and competition.
Vraylar remains a strong growth driver, reaching nearly $1.1 billion in global sales during fiscal Q3 2026, a 14.3% increase year-over-year. The company expects Vraylar sales to grow further to $4.2 billion in fiscal 2026 before the price cap takes effect. Meanwhile, AbbVie successfully defended its Botox Therapeutic product from an IRA price selection in a recent federal court ruling, though the government retains the right to appeal.
The company's financial resilience is supported by robust growth in its two largest franchises, Skyrizi and Rinvoq, which generated $17.6 billion and $8.3 billion respectively in fiscal 2025. Total revenue rose 10.3% in the third quarter of fiscal 2026 even as Imbruvica sales contracted. AbbVie has also demonstrated defensive characteristics during recent market shocks, falling less than the S&P 500 during tariff and inflation events.
Investors will closely monitor Vraylar's performance and guidance in February 2027 to determine if new growth can offset the anticipated price reductions. The stock's high valuation relies on reported earnings which are lower than adjusted measures, adding a layer of complexity to its investment case. Management expects top-tier growth to continue in 2027 despite the looming regulatory pressure.
๐ Stock gained 38.4% over the past twelve months, closing near yearly highs.
๐ Vraylar global sales hit $1.1 billion in Q3 2026 with a 14.3% increase.
โ ๏ธ IRA price cap on Vraylar creates a specific headwind starting in 2027.
๐ Imbruvica sales fell 26.1% in Q3 2026 due to IRA pricing pressure.
๐ฐ Skyrizi and Rinvoq generated $17.6B and $8.3B respectively in fiscal 2025.
๐ AbbVie stock returned 38.4% over the past twelve months, closing just 1.2% below its yearly high on November 6.
โ ๏ธ Management identified a specific headwind beginning in 2027: the Inflation Reduction Act (IRA) price cap on psychiatry drug Vraylar.
๐ Vraylar global sales reached nearly $1.1 billion in fiscal Q3 2026, marking a 14.3% increase year-over-year.
๐ Imbruvica sales fell 26.1% in fiscal Q3 2026 due to IRA pricing and competitive share pressure, serving as a precedent for Vraylar.
โ๏ธ A federal district court ruled in AbbVie's favor regarding Botox Therapeutic, stating the drug cannot be selected for IRA pricing due to its human serum albumin ingredient.
๐ Total revenue rose 10.3% in fiscal Q3 2026 despite a contraction in Imbruvica sales.
๐ฐ Skyrizi and Rinvoq generated $17.6 billion and $8.3 billion respectively in fiscal 2025, reflecting increases of 49.9% and 39.1%.
๐ AbbVie stock dropped only 13.0% during the 2025 tariff shock compared to a 19.0% decline for the S&P 500 index.
๐ฆ The stock trades at 49.8 times its last twelve months of earnings, significantly higher than the S&P 500's 21.8x multiple.
๐ Investors will watch Vraylar sales and fourth-quarter guidance when AbbVie reports in February 2027.
Bullish Signals
Stock returned 38.4% over past twelve months.
Vraylar sales reached $1.1B with 14.3% growth.
Total revenue rose 10.3% in Q3 2026.
Skyrizi and Rinvoq grew double-digits in 2025.
Court ruled favorably on Botox Therapeutic.
Risk Factors
IRA price cap on Vraylar starting 2027 creates revenue headwind.
Imbruvica sales fell 26.1% in Q3 2026 due to IRA pricing.
Trades at 49.8x earnings, significantly higher than S&P 500's 21.8x.
Reported earnings run well below adjusted measure, complicating valuation.
Bullish Signals
AbbVie stock returned 38.4% over the past twelve months, significantly outperforming the S&P 500's 9.8% return.
Vraylar global sales reached nearly $1.1 billion in fiscal Q3 2026, marking a strong 14.3% year-over-year increase.
Total revenue rose 10.3% in fiscal Q3 2026 even as the cancer drug Imbruvica experienced sales declines.
Skyrizi and Rinvoq, the company's two largest drugs, brought in $17.6 billion and $8.3 billion respectively in fiscal 2025 with double-digit growth.
A federal district court ruled in AbbVie's favor regarding Botox Therapeutic, preventing an immediate IRA price selection for the product.
Risk Factors
The Inflation Reduction Act (IRA) will impose a price cap on Vraylar starting in 2027, creating a specific headwind for future revenue.
Imbruvica sales fell 26.1% in fiscal Q3 2026 due to IRA pricing and competitive share pressure, setting a precedent for Vraylar's future performance.
AbbVie trades at 49.8 times its last twelve months of earnings, a valuation significantly higher than the S&P 500's 21.8x multiple.
Reported earnings run well below the company's adjusted measure, adding complexity to the stock's current valuation metrics.
AbbVie (ABBV) shares rose 2.27% to $301.54 following a solid quarterly report that beat market expectations and included raised guidance. DZ Bank, a German financial institution, has maintained its buy rating on the pharmaceutical giant while significantly increasing its target price from $288 to $345.
The bank highlighted that AbbVie's Q3 revenue reached $17.4 billion, representing a 10% increase and aligning with analyst expectations. Specifically, the Immunology division, which is central to the company's strategy, saw sales surge by 16% to $9.2 billion, driven by the successful transition from Humira to its successors, Skyrizi and Rinvoq.
Management has further strengthened the outlook by raising the full-year revenue forecast by $200 million to $67.8 billion and increasing the midpoint of adjusted EPS guidance by $0.11 to $13.97. DZ Bank emphasizes that the continued expansion of Skyrizi and Rinvoq through new indications, alongside growth in other therapeutic areas like Epkinly and Juvmo, broadens the revenue base beyond Immunology.
๐ AbbVie shares rose 2.27% after strong quarterly performance exceeding expectations.
๐ฐ Q3 revenue hit $17.4 billion, matching analyst forecasts with a 10% increase.
๐งฌ Immunology sales grew 16% to $9.2 billion as Skyrizi and Rinvoq replace Humira.
๐ Full-year revenue forecast raised by $200 million to $67.8 billion total.
๐ต Adjusted EPS guidance midpoint increased by $0.11 to $13.97 per share.
๐ AbbVie shares gained 2.27% to $301.54 after a strong quarterly performance that exceeded market expectations.
๐ฐ Q3 revenue reached $17.4 billion, marking a 10% year-over-year increase in line with analyst forecasts.
๐งฌ The Immunology division drove growth with sales rising 16% to $9.2 billion as Skyrizi and Rinvoq replace Humira.
๐ Management raised the full-year revenue forecast by $200 million to a new total of $67.8 billion.
๐ต Adjusted EPS guidance midpoint was increased by $0.11 to reach $13.97 per share.
๐ DZ Bank maintains a buy rating and raises its target price significantly from $288 to $345.
Bullish Signals
Shares rose 2.27% after beating market expectations.
Q3 revenue hit $17.4B, up 10%.
Immunology sales surged 16% to $9.2B.
Raised full-year forecast by $200M to $67.8B.
Adjusted EPS guidance increased to $13.97.
Bullish Signals
AbbVie shares rose 2.27% to $301.54 following a solid quarterly report that beat market expectations.
Q3 revenue reached $17.4 billion, up 10%, demonstrating strong top-line growth in line with analyst forecasts.
The Immunology division sales surged 16% to $9.2 billion as the company successfully transitions from Humira to Skyrizi and Rinvoq.
Management raised the full-year revenue forecast by $200 million to $67.8 billion, signaling confidence in future performance.
Adjusted EPS guidance midpoint was increased by $0.11 to $13.97, reflecting improved profitability outlook.
DZ Bank upgraded its target price from $288 to $345 while maintaining a buy rating on the stock.
AbbVie (ABBV) reported strong third-quarter results for Q3 2026, driving its stock price up approximately 3.1% to US$294.83 following the release. The company delivered net revenue of US$17.4 billion and basic earnings per share of US$2.38, representing significant growth compared to the prior year period.
The financial performance was bolstered by a substantial increase in adjusted EPS and operational revenue growth of 10.5%, primarily driven by its immunology and neuroscience portfolios. Key assets such as Skyrizi, Rinvoq, and Vraylar contributed to this expansion, validating the company's strategy of replacing declining blockbuster revenues with new pipeline successes.
However, investors remain cautious regarding potential headwinds in the oncology segment, where Imbruvica sales fell 29.4% operationally due to pricing pressures and competition. While management maintains guidance for total oncology revenue around US$6.6 billion for the full year, there is a noted risk that further erosion in this segment could offset gains from newer assets.
Despite these concerns, analysts view the stock as potentially undervalued at roughly 28% based on cash flow metrics. The company successfully closed the Apogee acquisition and highlighted progress on oncology candidates etentamig and epcoritamab, suggesting a robust pipeline capable of sustaining long-term growth.
๐ AbbVie Q3 2026 revenue rose 10.3% to US$17.4 billion.
๐ฐ EPS surged to US$2.38 from US$0.10 year-over-year.
๐งฌ Immunology and neuroscience segments drove 10.5% operational growth.
๐ Oncology revenue declined 29.4% due to pricing rules.
๐ AbbVie reported Q3 2026 net revenue of US$17.4 billion, marking a 10.3% year-over-year increase compared to the prior period.
๐ฐ Basic earnings per share surged to US$2.38 from US$0.10 in the previous year, reflecting a massive improvement in profitability.
๐งฌ Immunology and neuroscience segments drove operational revenue growth of 10.5%, supported by strong performance from Skyrizi, Rinvoq, and Vraylar.
๐ Oncology revenue faced headwinds with Imbruvica sales declining 29.4% operationally due to pricing rules and competitive share pressure.
๐ Management raised full-year adjusted earnings guidance following the release of strong third-quarter financial results.
๐ผ The company successfully closed the Apogee acquisition, adding to its portfolio of innovative therapies.
๐ฌ Progress was highlighted on oncology pipeline candidates etentamig and epcoritamab, indicating depth in the cancer franchise.
๐ต Cash flow analysis suggests the stock could be undervalued by approximately 28% based on current metrics.
๐ The stock price climbed roughly 21% over the past three months prior to the earnings release.
โ๏ธ Analysts note that while oncology pressure exists, it has not yet caused broad erosion across the entire segment.
Bullish Signals
Q3 2026 revenue hit US$17.4B, beating expectations.
Immunology/neuroscience segments grew 10.5% driven by Skyrizi/Rinvoq.
Cash flow suggests ~28% undervaluation based on own flows.
Risk Factors
Imbruvica sales fell 29.4% due to pricing rules and competition.
Older oncology pressure may offset newer asset growth.
Stock rose 21% pre-earnings, raising investor valuation concerns.
Bullish Signals
AbbVie reported strong Q3 2026 results with net revenue of US$17.4 billion and basic EPS of US$2.38, significantly beating market expectations.
The company achieved a 10.5% operational revenue growth in its immunology and neuroscience segments, driven by leaders like Skyrizi and Rinvoq.
Management successfully raised full-year adjusted earnings guidance following the release of robust third-quarter financial performance.
The stock price rose an additional 3.1% to US$294.83 immediately after the earnings announcement, reflecting positive investor sentiment.
Cash flow analysis indicates the company is potentially undervalued by approximately 28% when looking at its own cash flows.
The company closed the Apogee acquisition and highlighted significant progress on oncology pipeline candidates etentamig and epcoritamab.
Risk Factors
Imbruvica sales fell 29.4% operationally in Q3 2026 due to pricing rules and competitive share pressure, raising concerns about the oncology franchise.
There is a risk that further pressure on older oncology products could offset growth from newer assets and limit overall segment contribution.
Investors remain uneasy about paying up for a stock that had already risen roughly 21% over the past three months prior to earnings.
AbbVie announced a significant expansion of its research and development facility in Oxford, United Kingdom, involving an investment exceeding ยฃ120 million ($161 million). This strategic move aims to broaden the company's research capabilities across key therapeutic areas including immunology, neuroscience, and oncology. The new 12,000-square-foot site is designed to support advanced research focused on identifying novel disease targets and developing combination therapies for conditions with significant unmet medical needs.
The investment builds upon AbbVie's existing footprint in the UK, which was strengthened by its 2022 acquisition of Oxford-based biotechnology company DJS Antibodies. The company currently employs more than 1,100 people across its UK operations located in Oxford, Maidenhead, and Marlow. This expansion aligns with AbbVie's broader strategy to deepen collaborations with academic institutions, including partnerships with over 100 universities and research organizations in the UK annually.
A specific collaboration with the University of Oxford is highlighted, focusing on studying patient responses to treatments for inflammatory diseases throughout their illness. This research aims to guide future drug development efforts. The expansion occurs shortly after the US and Britain finalized an agreement regarding medicine pricing policies, though the primary focus of this news remains the capital investment in R&D infrastructure and scientific partnerships.
๐๏ธ AbbVie invests $161M to expand Oxford R&D facility.
๐ฌ New site enhances immunology, neuroscience, and oncology research.
๐ค Expansion strengthens UK portfolio following 2022 DJS Antibodies acquisition.
๐ฏ Efforts target new diseases and combination therapies for unmet needs.
๐ฅ Company employs over 1,100 people across UK operations.
๐๏ธ AbbVie is investing more than ยฃ120 million ($161 million) to expand its Oxford research and development facility.
๐ฌ The new 12,000-square-foot site will enhance research capabilities in immunology, neuroscience, and oncology.
๐ค This expansion builds on the company's 2022 acquisition of DJS Antibodies to strengthen its UK biotech portfolio.
๐ฏ Research efforts at the new site focus on identifying new disease targets and combination therapies for unmet medical needs.
๐ซ AbbVie collaborates with over 100 universities and research organizations in the UK, including a specific partnership with the University of Oxford.
๐ฅ The company employs more than 1,100 people across its UK operations in Oxford, Maidenhead, and Marlow.
Bullish Signals
AbbVie commits ยฃ120M ($161M) to expand UK R&D infrastructure.
Oxford facility expansion broadens research in immunology, neuroscience, oncology.
Partnerships with 100+ UK universities accelerate inflammatory disease drug development.
Bullish Signals
AbbVie is committing over ยฃ120 million ($161 million) to expand its R&D infrastructure in the UK, signaling strong confidence in its long-term research pipeline.
The expansion of the Oxford facility will broaden research capabilities across immunology, neuroscience, and oncology, diversifying the company's therapeutic focus.
Strategic collaborations with over 100 UK universities and a specific partnership with the University of Oxford aim to accelerate drug development for inflammatory diseases.
AbbVie (ABBV) recently announced a quarterly dividend increase of approximately 5.2%, raising the payout from $1.73 to $1.82 per share, with the next payment scheduled for February 16, 2027. This adjustment brings the new annualized dividend rate to $7.28, which covers roughly 52% of the company's raised adjusted EPS guidance ranging between $13.95 and $13.99.
The pharmaceutical giant is successfully transitioning its revenue base as Skyrizi and Rinvoq have replaced Humira as primary growth drivers. In the third quarter, Skyrizi revenue grew 22.7% to $5.78 billion while Rinvoq rose 23.9%, effectively offsetting a 31.2% decline in Humira sales driven by cheaper biosimilars taking market share.
AbbVie maintains its status as an S&P Dividend Aristocrat, reflecting a long history of annual dividend increases. The company's financial position is supported by strong growth in immunology and neuroscience segments, providing a wide cushion compared to peers like Pfizer whose dividends have remained frozen since early 2025.
๐ AbbVie raised quarterly dividend 5.2% to $1.82 payable Feb 16, 2027.
๐ฐ New annualized rate of $7.28 covers 52% of adjusted EPS guidance.
๐ Skyrizi and Rinvoq growth offset 31.2% Humira sales decline in Q3.
๐ AbbVie retains S&P Dividend Aristocrats Index status with consistent raises.
๐ Q3 adjusted EPS of $2.49 beat consensus estimate of $2.09.
๐ AbbVie raised its quarterly dividend by approximately 5.2% from $1.73 to $1.82, payable February 16, 2027.
๐ฐ The new annualized dividend rate of $7.28 covers about 52% of the company's adjusted EPS guidance of $13.95 to $13.99.
๐ Skyrizi revenue grew 22.7% to $5.78 billion in Q3, while Rinvoq rose 23.9%, offsetting a 31.2% drop in Humira sales.
๐ AbbVie retains its spot in the S&P Dividend Aristocrats Index due to a consistent record of annual dividend raises.
๐ Q3 adjusted EPS of $2.49 beat the consensus estimate of $2.09, excluding one-time deal charges.
๐ก๏ธ The company's dividend safety is bolstered by strong growth in immunology and neuroscience segments replacing legacy revenue.
Bullish Signals
Dividend increased 5.2% to $1.82.
Q3 EPS beat at $2.49.
Skyrizi and Rinvoq revenue grew.
Retains S&P Dividend Aristocrat status.
Payout covers 52% of EPS.
Risk Factors
Humira revenue declines as biosimilars gain share.
Growth depends on Skyrizi/Rinvoq sustaining high rates.
Bullish Signals
AbbVie increased its quarterly dividend by approximately 5.2% to $1.82, signaling confidence in future cash flows.
The company's Q3 adjusted EPS of $2.49 beat the consensus estimate of $2.09, demonstrating strong operational performance.
Skyrizi and Rinvoq drove significant revenue growth in Q3, with Skyrizi up 22.7% and Rinvoq up 23.9%, successfully replacing Humira as growth engines.
AbbVie maintains its S&P Dividend Aristocrat status, highlighting a long-term track record of increasing dividends annually.
The new dividend payout covers roughly 52% of adjusted EPS guidance, providing a wide safety margin compared to peers.
Risk Factors
AbbVie faces ongoing revenue pressure from Humira as cheaper biosimilars continue to take significant market share.
The company's growth strategy relies heavily on the successful transition to Skyrizi and Rinvoq, which must sustain high growth rates.
Drug approvalEarnings reportGuidance raisedAI-generated analysis
AbbVie reported a strongly positive third quarter with adjusted earnings per share of $3.82, beating guidance by $0.07, and net revenue reaching $17.4 billion, up 10.5% operationally. The company significantly raised its full-year outlook, increasing the adjusted EPS midpoint to $13.95-$13.99 and lifting the revenue forecast by $200 million to approximately $67.8 billion. This performance was driven by double-digit growth across nine key products, particularly in immunology and neuroscience segments.
The company's post-Humira growth strategy is gaining traction as Skyrizi sales rose 22.9% to nearly $5.8 billion and Rinvoq climbed 24.3% to $2.7 billion. AbbVie also highlighted robust performance in its oncology portfolio, where Venclexta sales increased 10.7%, helping to offset expected declines in Imbruvica due to competitive pressures and IRA-related pricing changes. The business generated approximately $14 billion in free cash flow during the first nine months.
Looking ahead, AbbVie raised its quarterly dividend by 5.2% to $1.82 per share starting in February 2027 and expects combined growth of $6 billion from Skyrizi and Rinvoq in 2026. While the company faces headwinds from biosimilar erosion on Humira, which fell 30.6%, and weakness in the aesthetics market with Juvรฉderm sales down 11.8%, management remains confident in delivering top-tier growth in 2027 supported by a productive pipeline and new indications for existing drugs.
๐ AbbVie beat Q3 EPS guidance by $0.07 at $3.82 adjusted.
๐ฐ Revenue hit $17.4B, up 10.5% and exceeding expectations by $200M.
๐ Full-year EPS guidance raised to $13.95-$13.99 with revenue lifted to $67.8B.
๐ต AbbVie generated approximately $14 billion in free cash flow during the first nine months of the year.
๐ The company will raise its quarterly dividend by 5.2% to $1.82 per share beginning in February 2027.
๐ฎ Management expects Skyrizi and Rinvoq to produce combined growth of $6 billion in 2026.
โ๏ธ AbbVie remains focused on reaching a net leverage ratio of 2x within two to three years.
Bullish Signals
Adjusted Q3 earnings hit $3.82, beating guidance midpoint.
Net revenue reached $17.4B, up 10.5% operationally.
Raised full-year adjusted EPS guidance to $13.95-$13.99.
Skyrizi sales rose 22.9% to nearly $5.8 billion.
Rinvoq sales climbed 24.3% to $2.7 billion.
Risk Factors
Humira revenue fell 30.6% due to biosimilar competition.
Imbruvica sales dropped 26.1%, lowering guidance to $2.1B.
Aesthetics revenue declined 1.8% as Juvรฉderm sales fell 11.8%.
Economic uncertainty and lower consumer confidence hurt aesthetics.
Vraylar IRA price pressure begins in 2027.
FDA issues outstanding on Boey manufacturing matters.
Bullish Signals
AbbVie reported adjusted Q3 earnings of $3.82, beating the guidance midpoint by $0.07.
Net revenue reached $17.4 billion, up 10.5% operationally and $200 million above expectations.
The company raised full-year adjusted EPS guidance to $13.95-$13.99 and lifted the revenue forecast to $67.8 billion.
Skyrizi sales rose 22.9% to nearly $5.8 billion, capturing roughly one in two new psoriasis patients.
Rinvoq sales climbed 24.3% to $2.7 billion, with commercialization expanding into vitiligo and alopecia areata.
Neuroscience revenue grew 19.5% operationally to nearly $3.4 billion, driven by Vraylar and Ubrelvy growth.
AbbVie completed the acquisition of Apogee Therapeutics, gaining assets in dermatology and respiratory disease.
The Phase III EPCORE DLBCL-2 study found Epkinly plus R-CHOP cut disease progression risk by 51%.
AbbVie generated approximately $14 billion in free cash flow during the first nine months of the year.
The company will raise its quarterly dividend by 5.2% to $1.82 per share beginning in February 2027.
Risk Factors
Humira revenue fell 30.6% operationally to $683 million as biosimilar competition continued to erode sales.
Imbruvica sales dropped 26.1% due to competitive share losses and IRA-related pricing pressure, lowering full-year guidance to $2.1 billion.
Aesthetics revenue declined 1.8% operationally with Juvรฉderm sales down 11.8% amid continued weakness in dermal-filler markets.
Management cited economic uncertainty and lower consumer confidence as factors contributing to the decline in aesthetics revenue.
The IRA price for Vraylar will begin in 2027, representing a future pressure on the franchise's financial performance.
AbbVie is working with the FDA on outstanding issues connected with the complete response letter for Boey regarding manufacturing and chemistry matters.
AbbVie (ABBV) has successfully transitioned from its blockbuster drug Humira without shrinking, driven by rapid growth in Skyrizi and Rinvoq. Over the past twelve months, revenue reached $64.39 billion with a 10.20% increase in the most recent quarter, significantly outpacing rival Bristol Myers Squibb (BMY) which grew at 5.70%. AbbVie maintains a robust 40.04% operating margin and generated $16.87 billion in levered free cash flow, demonstrating strong operational execution despite the high cost of acquisitions.
However, the market valuation tells a different story compared to operational performance. While AbbVie is viewed as the superior business with sustainable growth from early-stage patent protection on its new drugs, Bristol Myers trades at a significant discount, offering a forward price-to-earnings multiple of 9.36 times versus 16.39 times for AbbVie. Bristol Myers also boasts a higher net margin of 18.87% compared to AbbVie's 9.80%, and a return on equity of 46.60% against AbbVie's lower returns, largely due to the interest and amortization burdens from AbbVie's acquisition strategy.
The article concludes that while AbbVie is the better business with faster growth and higher operating margins, Bristol Myers represents the better-priced investment opportunity for value-oriented investors. Bristol Myers shares have outperformed AbbVie over the last twelve months, rising 35.23% compared to AbbVie's gains, as the market reprices the supposed laggard. Investors are paying a premium for AbbVie's completed transition while Bristol Myers offers higher yields and better bottom-line profitability metrics at a cheaper multiple.
๐ AbbVie revenue grew 10.20% in the latest quarter driven by Skyrizi and Rinvoq.
AbbVie (ABBV) has delivered a significant 196.7% share price return over the past five years, prompting investors to scrutinize whether current valuations are supported by durable cash generation rather than market sentiment. The article analyzes the company's financial health through a Discounted Cash Flow (DCF) lens, noting that recent positive Phase 3 data for etentamig in multiple myeloma supports expectations for ongoing growth despite the stock trading at $290.79.
According to the DCF model presented, AbbVie generated approximately $18.3 billion in free cash flow over the last twelve months. Forecasts project this figure to reach around $40 billion annually by 2030 before tapering, a trajectory typical for a mature pharmaceutical group with a broad pipeline. The analysis concludes that the estimated intrinsic worth of AbbVie sits substantially above its current market price based on these cash flow assumptions.
Community narratives and fundamental analysis suggest the stock is roughly fairly valued, contingent on successful execution of its pipeline to replace revenue from declining products like Humira and Imbruvica. While the company faces risks associated with product transitions and pricing power, the core thesis relies on the business's ability to generate robust future cash flows that justify the high P/E ratio of 82.0x.
Simply Wall St highlights that while price growth stories are compelling, quieter risk indicators must be monitored before settling on a final valuation. The article emphasizes that the company's fair value is testable based on specific paths for growth and profitability required to materially increase or decrease its market worth relative to today's price.
๐ AbbVie delivered 196.7% share price return over last five years.
๐ฐ Company generated $18.3 billion free cash flow in trailing twelve months.
AbbVie (ABBV) has delivered a 646% total return over the last decade, turning $1,000 into $7,464 and significantly outperforming the S&P 500's 263% price gain. The company successfully navigated the loss of exclusivity for its flagship drug Humira in early 2023, which saw sales fall 35.9% to $756M in Q2 2026, by relying on strong growth from its replacement pipeline.
The core of AbbVie's recent performance is driven by Skyrizi and Rinvoq, which grew 24.4% and 24.5% respectively in Q2 2026 to reach $5.505B and $2.525B in sales. The company also benefits from its $63B Allergan acquisition, which added Botox and Vraylar, and a pending $10.9B acquisition of Apogee Therapeutics designed to deepen its immunology pipeline.
AbbVie offers a robust income profile with a quarterly dividend that tripled from $0.57 in 2016 to $1.73 today, resulting in a forward annual yield of roughly 2.30%. While the stock trades above the average analyst target of $283.19 and carries a high trailing P/E of 120 due to acquisition charges, the forward P/E is more reasonable at 18. Investors face risks regarding further declines in Humira and Imbruvica sales, as well as negative shareholders' equity.
Analysts note that future optimism depends on Skyrizi and Rinvoq maintaining mid-20% growth rates and the successful integration of Apogee. The primary concern remains whether these new drugs can fully offset the rapid erosion of Humira and Imbruvica revenues, particularly as Imbruvica dropped 29.4% in the last quarter.
๐ AbbVie delivered 646% total return over 10 years, outperforming S&P 500.
๐ Skyrizi and Rinvoq sales grew 24%+, offsetting Humira's decline.
๐ค Company pursues pending $10.9B Apogee Therapeutics acquisition.
๐ฐ Quarterly dividend tripled to $1.73 with ~2.30% forward yield.
AbbVie Inc. (ABBV) is currently rated as a 'Hold' because its valuation appears to already price in optimistic growth expectations, despite the company possessing a promising pipeline of new assets.
The company is expected to achieve double-digit revenue growth in the near term, driven primarily by its biosimilars Skyrizi and Rinvoq, as well as neuroscience assets. However, this growth trajectory faces a significant headwind from an impending patent cliff in the early 2030s.
To justify current stock prices, AbbVie must sustain approximately 10% annual revenue growth for the next decade. This target is considered challenging given that over $20 billion in revenue is at risk of exclusivity loss during this period.
Financial flexibility remains a concern due to the company's high debt levels and heavy dividend commitments. While current operations are described as stable, these capital constraints warrant close monitoring by investors.
๐ Hold rating due to valuation pricing in optimistic growth.
๐ Near-term double-digit revenue growth driven by Skyrizi and Rinvoq.
โณ Patent cliff in early 2030s threatens over $20B revenue.
๐ Needs sustained 10% annual growth to justify current prices.
๐ฐ High debt restricts capital flexibility for AbbVie.
๐ AbbVie is rated a 'Hold' because current valuation prices in optimistic growth despite a promising pipeline.
๐ Double-digit revenue growth is expected in the near term driven by Skyrizi, Rinvoq, and neuroscience assets.
โณ A patent cliff looms in the early 2030s threatening over $20 billion in revenue exclusivity.
๐ To justify current prices, AbbVie needs to sustain 10% annual growth for a decade.
๐ฐ High debt and heavy dividend commitments restrict capital flexibility at AbbVie.
Bullish Signals
Revenue expected to grow double-digits from Skyrizi, Rinvoq, neuroscience.
Risk Factors
Patent cliff hits $20B+ revenue by early 2030s.
High debt limits capital flexibility due to dividends.
Bullish Signals
Double-digit revenue growth is expected in the near term driven by Skyrizi, Rinvoq, and neuroscience assets.
Risk Factors
A patent cliff looms in the early 2030s with over $20 billion in revenue facing exclusivity loss.
High debt and heavy dividend commitments restrict capital flexibility at AbbVie.
AbbVie (ABBV) recently received U.S. FDA approval for a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn's disease, offering patients a home-based treatment option via an on-body injector. This regulatory milestone adds to the company's pipeline of product news and reinforces its strategic focus on expanding indications for its key franchise.
Financially, AbbVie has demonstrated strong momentum with a 1-month share price return of 8.47% and a year-to-date return of 25.04%, supported by robust multi-year total shareholder returns. Management reports that the erosion of Humira revenue, approximately US$18 billion, has been effectively offset by roughly US$28 billion in growth from other platforms, with 2026 guidance projected to be nearly US$10 billion above pre-Humira peak levels.
Valuation perspectives on AbbVie are mixed. While the stock trades slightly above the average analyst target and a specific fair value estimate of $284.79 suggests it is currently overvalued by about 1%, a discounted cash flow (DCF) model indicates substantial upside, valuing the shares at approximately $503.55 based on future cash flows. This divergence highlights a debate over whether the stock is expensive on current earnings or undervalued regarding long-term cash generation potential.
Investors must weigh these positive growth signals against specific risks that could alter the company's narrative. Key concerns include potential pricing pressure from U.S. drug negotiations and the possibility that key oncology investments underperform expectations. These factors, alongside the mixed valuation signals, create a complex investment case requiring careful stress testing of underlying assumptions.
๐ FDA approved home-based SKYRIZI induction for Crohn's disease.
๐ Stock rose 8.47% last month and 25.04% year-to-date.
๐ฐ US$18B Humira erosion offset by US$28B other platform growth.
AbbVie (ABBV) is approaching its October 30 earnings report with shares up 28.55% year-to-date, though options pricing suggests a volatile 5% swing in either direction. The stock has historically sold off even after beating estimates, as seen in previous quarters where it fell despite positive results, indicating that management's guidance is critical for sustaining the rally.
Financially, AbbVie's immunology portfolio remains robust with Skyrizi and Rinvoq generating nearly half of total revenue. Skyrizi grew 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion in the last quarter, effectively offsetting a significant 35.9% decline in Humira sales. The company recently received FDA approvals for Juvmo for Parkinson's disease and a new subcutaneous induction regimen for Skyrizi in Crohn's disease.
Despite strong product performance, AbbVie trimmed its full-year adjusted EPS guidance to $13.87-$14.07 due to dilution from the Apogee Therapeutics acquisition, which costs roughly $0.14 per share. Analysts expect a sharp profit rebound in the upcoming quarter as the year-ago period included a one-time $1.50 acquired IPR&D charge. The company trades near 20x full-year consensus EPS, and investors will be watching for confirmation that operational strength offsets the drag from the Apogee deal.
๐ Shares rallied 28.55% YTD ahead of earnings with options pricing a 5% swing.
๐ Skyrizi and Rinvoq revenue grew ~24%, nearly half of total revenue.
๐ฌ FDA approved Juvmo for Parkinson's and Skyrizi induction regimen for Crohn's.
๐ฐ EPS guidance trimmed to $13.87-$14.07 due to $0.14/share dilution from Apogee deal.
โ ๏ธ Shares fell 4.45% and 2.51% on prior earnings days despite beating estimates.
๐ AbbVie shares have rallied 28.55% year-to-date ahead of the October 30 earnings report, with options pricing a roughly 5% swing on the release.
๐ Skyrizi revenue grew 24.4% to $5.51 billion while Rinvoq rose 24.5% to $2.53 billion, nearly half of total revenue.
๐ Humira sales slid 35.9%, but strong immunology growth more than compensated for the decline in the last quarter.
๐ฌ The FDA approved Juvmo (tavapadon) for Parkinson's disease and Skyrizi's subcutaneous induction regimen for Crohn's disease recently.
๐ฐ Management trimmed full-year adjusted EPS guidance to $13.87-$14.07 due to $0.14 per share dilution from the Apogee Therapeutics deal.
๐ Revenue guidance was raised by $300 million to approximately $67.6 billion for the full year.
๐ง Neuroscience revenue grew 20.3% to $3.23 billion, with Vyalev expected to reach blockbuster sales this year.
โ ๏ธ Recent history shows shares fell 4.45% and 2.51% on earnings days after beating estimates in Q3 2025 and Q2 2026 respectively.
๐ Imbruvica sales fell 29.4% and Juvederm slipped 6.0% in the second quarter, adding pressure to top-line growth.
๐ฏ Analyst consensus EPS of $3.78 sits below management's target of $3.84-$3.88 after eight downward revisions over 30 days.
Bullish Signals
Skyrizi revenue grew 24.4% to $5.51 billion.
Rinvoq rose 24.5% to $2.53 billion.
FDA approved Juvmo for Parkinson's disease.
Neuroscience revenue grew 20.3% to $3.23 billion.
Risk Factors
Guidance cut due to $0.14 dilution from Apogee deal.
Bullish Signals
Skyrizi revenue grew 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion, generating nearly half of total company revenue.
The FDA approved Juvmo for Parkinson's disease and Skyrizi's subcutaneous induction regimen for Crohn's disease, expanding the pipeline.
Revenue guidance was raised by $300 million to about $67.6 billion despite trimming EPS guidance due to acquisition costs.
Neuroscience revenue grew 20.3% to $3.23 billion last quarter with Vyalev expected to become a blockbuster this year.
Management reported "absolutely no degradation" in Skyrizi new starts following the launch of a rival product.
Risk Factors
Management trimmed full-year adjusted EPS guidance to $13.87-$14.07 due to $0.14 per share dilution from the Apogee Therapeutics deal.
Humira sales slid 35.9% in the last quarter, and the pace of erosion still determines how much immunology gain reaches the top line.
Imbruvica sales fell 29.4% and Juvederm slipped 6.0% in the second quarter, creating drag on overall revenue growth.
The stock has a recent habit of selling off even after beating estimates, falling 4.45% and 2.51% on previous earnings days.
Analyst consensus EPS of $3.78 sits below management's target of $3.84-$3.88 following eight downward revisions over the past 30 days.
AbbVie (ABBV) received FDA approval on October 23, 2026, for a subcutaneous induction regimen of SKYRIZI in adults with moderately to severely active Crohn's disease. This expansion includes an on-body injector option designed to improve patient convenience and accelerate early disease control, supporting the company's medium-term revenue growth strategy as it transitions away from legacy products.
Financially, ABBV reported a modest earnings beat for the quarter ended July 31, 2026, with EPS of $3.65 versus estimates of $3.61. The stock is currently trading at $285.64, near its 52-week high, but carries a trailing P/E ratio of 80.47 and limited implied upside to the consensus price target of $294, suggesting the stock is fairly valued to slightly rich on a near-term basis.
Analysts maintain a constructive stance despite valuation concerns, with Goldman Sachs raising its price target to $294 following the regulatory win. However, investors are monitoring liquidity metrics, including a current ratio of 0.81 and negative return on equity, alongside upcoming earnings on October 30, 2026, which will provide critical updates on SKYRIZI uptake and capital allocation plans.
๐ FDA approved subcutaneous SKYRIZI regimen for Crohn's on October 23, 2026.
๐ฐ Q2 2026 EPS beat estimates at $3.65 driven by specialty biologics.
โ ๏ธ Current ratio of 0.81 signals liquidity concerns as liabilities exceed assets.
๐ Goldman Sachs raised price target to $294 with Strong Buy rating.
๐ Stock trades at P/E of 80.47 with limited upside to consensus.
๐ On October 23, 2026, the FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn's disease, expanding patient access via an on-body injector.
๐ฐ AbbVie reported Q2 2026 EPS of $3.65, beating estimates of $3.61, driven by resilient revenue from specialty biologics.
๐ The stock trades at a trailing P/E of 80.47 with limited implied upside to the consensus price target of $294.
โ ๏ธ Liquidity metrics warrant monitoring as the current ratio stands at 0.81, indicating current liabilities exceed short-term assets.
๐ Goldman Sachs maintained a Strong Buy rating and raised its price target from $258 to $294 following the FDA action.
๐ Upcoming earnings on October 30, 2026, will focus on SKYRIZI uptake, margin expansion, and capital allocation revisions.
๐ The stock has largely stopped making Humira central to its investor narrative as it pivots toward newer assets like SKYRIZI.
Bullish Signals
FDA approved SKYRIZI subcutaneous induction for Crohn's disease.
EPS beat estimates at $3.65 for Q2 2026.
Goldman Sachs raised price target to $294.
Strong dividend profile with large market cap.
Risk Factors
Current ratio of 0.81 shows liquidity concerns.
Negative ROE and P/B reflect buybacks, not weakness.
Implied upside is only 2.9%, suggesting fair value.
Bullish Signals
AbbVie secured FDA approval for a subcutaneous induction regimen of SKYRIZI in Crohn's disease, expanding the label and improving patient convenience.
The company delivered an EPS beat of $3.65 versus estimates of $3.61 for the quarter ended July 31, 2026.
Goldman Sachs raised its price target to $294 following the regulatory win, signaling confidence in SKYRIZI's commercial potential.
AbbVie maintains a durable dividend profile and a large market capitalization while transitioning revenue streams toward newer biologics.
Risk Factors
Liquidity metrics are concerning with a current ratio of 0.81, indicating that current liabilities exceed short-term assets.
Return on equity is negative and price-to-book is negative, reflecting large share buybacks and accumulated intangible assets rather than operational weakness.
Implied upside to the consensus price target is only about 2.9%, suggesting the stock is fairly valued to slightly rich on a near-term basis.
AbbVie (ABBV) has seen a shift in analyst sentiment, with fair value estimates rising to US$284.79 from US$278.61 and price targets clustering between US$260 and US$325. Major financial institutions including Barclays, JPMorgan, Morgan Stanley, BofA, HSBC, and Piper Sandler have raised their targets, citing confidence in the company's core immunology, neuroscience, and oncology portfolios.
Analysts specifically highlight strong execution on recent quarters and progress in key assets such as Skyrizi, Rinvoq, Vraylar, and Vyalev. The breadth of AbbVie's late-stage pipeline and strategic M&A activity, including the Apogee acquisition and collaborations like Xilio's TCE platform, are viewed as supporting longer-term growth options beyond the erosion of Humira.
Despite the bullish outlook on core drivers, specific risks have tempered expectations for certain programs. RBC Capital and Guggenheim flagged underwhelming efficacy in Phase 3 data for lutikizumab in hidradenitis suppurativa, noting limited potential as a monotherapy. Additionally, Goldman Sachs and Cantor Fitzgerald pointed to weaker efficacy compared to competitors and crowded positioning in the stock as headwinds that raise the bar for upcoming results.
Simply Wall St updated its financial forecasts reflecting these narrative shifts, projecting revenue growth of 8.21% and a net profit margin of 29.49%. The analysis emphasizes how growth from immunology drugs is being used to offset Humira erosion, while acknowledging key risks such as loss of exclusivity for major products, rising pricing pressure from US drug negotiations, and competitive headwinds in oncology affecting Imbruvica.
๐ Analyst fair value raised to US$284.79 with targets between US$260-US$325.
๐ฌ Major firms raise targets citing confidence in Skyrizi, Rinvoq, and oncology.
๐ผ Apogee acquisition viewed as key driver for long-term diversification.
โ ๏ธ RBC flags underwhelming Phase 3 efficacy for lutikizumab in hidradenitis suppurativa.
๐ Forecasts project revenue growth of 8.21% and net profit margin of 29.49%.
๐ Analyst fair value for AbbVie increased to US$284.79, with price targets clustering between US$260 and US$325.
๐ฌ Major firms including JPMorgan and BofA raised targets citing confidence in Skyrizi, Rinvoq, and oncology portfolios.
๐ผ Strategic M&A activity, specifically the Apogee acquisition, is viewed as a key driver for long-term diversification.
โ ๏ธ RBC Capital flagged underwhelming Phase 3 efficacy for lutikizumab in hidradenitis suppurativa, tempering expectations.
๐ Goldman Sachs noted AbbVie's lutikizumab appears weaker than key competitors in the hidradenitis suppurativa space.
๐ Updated financial forecasts project revenue growth of 8.21% and a net profit margin of 29.49%.
Bullish Signals
Fair value raised to US$284.79 on improved metrics.
Major firms raise targets citing strong portfolio execution.
Pipeline breadth and Apogee acquisition support growth.
Skyrizi/Rinvoq growth offsets Humira erosion.
Risk Factors
Lutikizumab Phase 3 data showed underwhelming efficacy.
Efficacy weaker than key competitor in hidradenitis suppurativa.
Crowded positioning raises bar for upcoming results.
Risks: loss of exclusivity and rising pricing pressure.
Bullish Signals
Analyst fair value increased to US$284.79 from US$278.61, reflecting improved valuation metrics.
Multiple major firms including JPMorgan, Morgan Stanley, and BofA raised price targets citing strong execution in immunology and neuroscience portfolios.
The breadth of the late-stage pipeline and recent M&A activity, including the Apogee acquisition, support longer-term growth options.
Analysts express confidence that growth from Skyrizi and Rinvoq will effectively offset Humira erosion.
Risk Factors
RBC Capital and Guggenheim flagged underwhelming efficacy in Phase 3 INTREPID hidradenitis suppurativa data for lutikizumab.
Goldman Sachs and Cantor Fitzgerald noted that AbbVie's lutikizumab efficacy appears weaker than a key competitor in hidradenitis supsurpiva.
Crowded positioning in the stock raises the bar for upcoming results, according to analyst commentary.
Key risks include loss of exclusivity for major products and rising pricing pressure from US drug price negotiations.
AbbVie (NYSE: ABBV) shares have climbed 26% year-to-date driven by strong financial performance and a bright medium-term outlook. The company's two primary growth pillars, Skyrizi and Rinvoq, are performing robustly, with Skyrizi generating nearly $10 billion in sales for the first half of the year, representing a 27% increase over the prior period.
To mitigate future patent expirations, AbbVie is advancing next-generation therapies. On October 19, the company announced positive Phase 2a results for ABBV-466, a combination immunology drug showing higher remission rates in Crohn's disease than current monotherapies. Additionally, the firm recently acquired Apogee Therapeutics for $10.9 billion to gain access to zumilokibart, a potential competitor to Sanofi's Dupixent.
Beyond its core immunology portfolio, AbbVie maintains strong positions in other therapeutic areas including migraine (Qulipta), schizophrenia (Vraylar), and oncology (Venclexta). The company also boasts an attractive dividend profile as a Dividend King with 50 consecutive years of increases and a forward yield of 2.5%, significantly outpacing the S&P 500 average.
๐ Shares rose 26% this year on strong results and pipeline.
๐ Skyrizi generated nearly $10 billion in first-half sales.
๐ฌ Next-gen drug ABBV-466 showed higher Crohn's remission rates.
๐ฐ Acquired Apogee Therapeutics for $10.9 billion to bolster portfolio.
๐ Rinvoq protected from generics in U.S. until 2037.
๐ AbbVie shares have risen 26% this year supported by strong financial results and a robust pipeline.
๐ Skyrizi generated nearly $10 billion in sales for the first half of the year, up 27% year over year.
๐ฌ Phase 2a results for next-gen drug ABBV-466 showed higher remission rates in Crohn's disease than current treatments.
๐ฐ AbbVie acquired Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio with zumilokibart.
๐ Rinvoq is protected from generic competition in the U.S. market until 2037.
๐ The company holds Dividend King status with 50 consecutive years of dividend increases and a 2.5% forward yield.
Bullish Signals
Shares up 26% YTD on strong performance.
Skyrizi sales hit $10B, up 27%.
ABBV-466 shows higher Crohn's remission rates.
Acquired Apogee for $10.9B to gain zumilokibart.
Rinvoq protected from generics until 2037.
Dividend King with 50 years of increases.
Bullish Signals
AbbVie shares have climbed 26% year-to-date driven by strong financial performance and a bright medium-term outlook.
Skyrizi generated nearly $10 billion in sales for the first half of the year, representing a 27% increase over the prior period.
Phase 2a results for next-gen drug ABBV-466 showed higher remission rates in Crohn's disease than current monotherapies, suggesting a strong successor to Skyrizi.
The company acquired Apogee Therapeutics for $10.9 billion to gain access to zumilokibart, a potential blockbuster competitor to Sanofi's Dupixent.
Rinvoq is protected from generic competition in the U.S. market until 2037, ensuring sustained revenue growth.
AbbVie holds Dividend King status with 50 consecutive years of dividend increases and offers a forward yield of 2.5%.
AbbVie (ABBV) presented primary Phase 2a data for ABBV-466, an investigational two-drug combination therapy for Crohn's disease, at a gastroenterology meeting in Barcelona on October 19. At Week 24, the combination achieved endoscopic remission in 40.5% of patients compared to 22.4% for Skyrizi alone, representing a significant improvement in efficacy. However, results at the primary Week 12 endpoint showed the combination reached 30.2% remission versus 21.3% for Skyrizi monotherapy. The study was open-label with 300 patients, and serious adverse events were comparable between the groups at 10.4% and 9.6%, respectively.
AbbVie's Chief Commercial Officer Jeff Stewart indicated that commercial payoff for the combination therapy is expected in the early 2030s, while a nearer-term catalyst involves subcutaneous Skyrizi induction for Crohn's, which the FDA expects to approve in the fourth quarter. CEO Rob Michael highlighted the company's successful transition from Humira, noting that ex-Humira growth platforms have offset $18 billion in erosion, with Skyrizi and Rinvoq generating $25.87 billion in sales in 2025 compared to Humira's peak of $20.69 billion in 2021.
Despite the positive clinical data, AbbVie shares slipped 0.96% on October 19 to close at $282.68, leaving the stock up roughly 24% for 2026 and trading near the Street's mean target price of approximately $367. The company also lowered its 2026 adjusted EPS guidance to a range of $13.76 to $13.96 due to a one-time $216 million pre-tax charge related to acquired research, which impacted the third-quarter outlook.
Analysts and models suggest that achieving adjusted EPS at or above the average estimate of $3.79, combined with the anticipated subcutaneous Skyrizi approval, would support the stock trading at its mean target. The company's long-term growth strategy relies on maintaining market share for Skyrizi and Rinvoq while extending growth into the 2030s through new combination therapies like ABBV-466.
๐ ABBV-466 combo therapy achieved 40.5% remission vs 22.4% for Skyrizi alone at Week 24.
๐ FDA approval expected Q4 for subcutaneous Skyrizi induction in Crohn's disease.
๐ Skyrizi and Rinvoq generated $25.87 billion sales, surpassing Humira's peak of $20.69 billion.
๐ 2026 adjusted EPS guidance lowered to $13.76-$13.96 due to $216 million one-time charge.
โ ๏ธ Shares slipped 0.96% on Oct 19 despite trading near consensus estimates.
๐ AbbVie presented primary Phase 2a results for ABBV-466 showing 40.5% endoscopic remission at Week 24 versus 22.4% for Skyrizi alone.
๐ฌ The investigational combination therapy demonstrated a 1.8x improvement in remission rates compared to Skyrizi monotherapy at the Week 24 endpoint.
๐ AbbVie expects FDA approval for subcutaneous Skyrizi induction for Crohn's in the fourth quarter of this year.
๐ Skyrizi and Rinvoq generated $25.87 billion in sales in 2025, exceeding Humira's peak annual sales of $20.69 billion.
๐ฐ CEO Rob Michael stated that ex-Humira growth has fully offset the $18 billion decline from the original blockbuster drug.
๐ AbbVie lowered its 2026 adjusted EPS guidance to $13.76-$13.96 due to a $216 million one-time pre-tax charge.
๐ The company's commercial payoff for the ABBV-466 combination therapy is projected for the early 2030s.
๐ฏ Wall Street analysts maintain a mean target price of approximately $367, implying roughly 30% total return potential.
โ ๏ธ Shares slipped 0.96% on October 19 following the clinical data release, trading near consensus estimates.
๐ The Phase 2a study included 300 patients where 75% had failed at least one advanced therapy prior to enrollment.
Bullish Signals
ABBV-466 achieved 40.5% remission vs 22.4% for Skyrizi at Week 24.
Skyrizi and Rinvoq generated $25.87B sales in 2025, surpassing Humira's peak.
Ex-Humira growth platforms fully offset the $18 billion erosion from Humira.
FDA approval expected for subcutaneous Skyrizi induction for Crohn's in Q4.
Risk Factors
$216M pre-tax charge lowered 2026 EPS guidance to $13.76-$13.96.
ABBV-466 primary endpoint showed only 1.4x improvement at Week 12.
Bullish Signals
AbbVie's investigational combination therapy ABBV-466 achieved 40.5% endoscopic remission at Week 24, significantly outperforming Skyrizi monotherapy which reached 22.4%.
The company successfully transitioned its revenue base with Skyrizi and Rinvoq generating $25.87 billion in sales in 2025, surpassing Humira's peak of $20.69 billion.
CEO Rob Michael confirmed that ex-Humira growth platforms have fully offset the $18 billion erosion from the original blockbuster drug.
AbbVie expects FDA approval for subcutaneous Skyrizi induction for Crohn's in the fourth quarter, providing a near-term commercial catalyst.
Risk Factors
AbbVie lowered its 2026 adjusted EPS guidance to $13.76-$13.96 due to a $216 million pre-tax charge related to acquired research.
The primary endpoint for the ABBV-466 combination therapy at Week 12 showed only a 1.4x improvement over Skyrizi alone, falling short of the doubling seen at Week 24.
JPMorgan raised its price target for AbbVie Inc. (ABBV) to USD 300 on October 8, 2026, marking a significant increase from the previous target of USD 285. This bullish analyst action follows the company's strong second-quarter financial performance, where revenue surged 10.20% year-over-year to reach USD 16.99 billion. The stock was trading at EUR 254.35 on October 19, 2026, positioning it near the upper end of its 52-week range.
The company's financial results highlight a strategic transition period where legacy franchise growth is being offset by declines in key products like Humira, which saw revenue drop 35.90% to USD 756 million. Despite this specific decline, newer medicines successfully drove total sales higher, validating the importance of the company's pipeline for future valuation. Adjusted earnings per share climbed to USD 3.65, a substantial increase from USD 2.97 in the prior-year quarter.
Looking ahead, AbbVie is guiding for third-quarter adjusted earnings per share between USD 3.84 and USD 3.88, with results scheduled for release on October 30, 2026. Investors will also be watching for the upcoming dividend payment of USD 1.73 per share set for November 16, 2026. The market capitalization stands at approximately USD 504.4 billion as of mid-October.
๐ JPMorgan raised AbbVie price target to USD 300 on October 8, 2026.
๐ฐ Q2 revenue grew 10.20% YoY to USD 16.99 billion.
๐ New medicines offset Humira declines, driving total sales growth.
๐ต Adjusted EPS rose to USD 3.65 from USD 2.97 prior year.
๐ธ Q3 adjusted EPS guidance set between USD 3.84 and USD 3.88.
๐ JPMorgan raised its price target for AbbVie to USD 300 from USD 285 on October 8, 2026.
AbbVie (ABBV) recently saw a significant increase in stake by Citadel's Ken Griffin, who added 2.7 million shares in Q2 2026 at prices in the low $200s, representing a 546% jump in his position. However, the article clarifies that this investment thesis is now outdated as the stock has appreciated to approximately $285 per share, moving past analyst targets set in August.
The company maintains its status as a Dividend King with a 50+ year streak of dividend increases, currently offering a 2.4% yield at the current price. This growth is driven by strong performance from its key immunology drugs, Skyrizi and Rinvoq, which combined generated over $8 billion in revenue in Q2 despite the continued decline of Humira.
Despite the robust dividend history, financial metrics indicate a tightening cushion with free cash flow coverage dropping to 1.5x and net debt reaching $64 billion. The company recently cut its 2026 EPS guidance due to high acquisition-related expenses, signaling that growth is being funded by significant borrowing rather than organic cash generation.
Analysts view the current valuation as fair rather than a bargain, with a forward P/E of roughly 20x reflecting a quality compounder at a reasonable price. The investment case remains valid for long-term income investors willing to accept a fair entry point and wait for growth engines to compound value, though the specific discount sought by previous investors is no longer available.
๐ Citadel added 2.7M shares to AbbVie stake before price rose to $285.
๐ Skyrizi and Rinvoq revenue grew ~24% offsetting Humira decline in Q2.
โ ๏ธ Dividend payout ratio increased from 41% to 65% weakening cash flow coverage.
๐ AbbVie cut 2026 EPS guidance midpoint to $13.86 due to acquired expenses.
๐ฐ Net debt stands at $64B with leverage ratio of 2.26x EBITDA.
๐ Ken Griffin's Citadel increased its AbbVie stake by 546% in Q2 2026, adding 2.7 million shares at prices around $200 before the stock rose to $285.
๐ The company maintains a 50+ year dividend growth streak with a current yield of 2.4% based on the $1.73 quarterly payout.
๐ Skyrizi revenue grew 24.4% to $5.5 billion and Rinvoq rose 24.5% to $2.5 billion in Q2, offsetting Humira's decline.
โ ๏ธ Free cash flow coverage of dividends has weakened to 1.5x as the payout ratio increased from 41% to 65% between fiscal 2022 and 2025.
๐ฐ Net debt stands at $64 billion with a leverage ratio of 2.26x EBITDA, funded by acquisitions like the pending $10.9 billion Apogee Therapeutics deal.
๐ AbbVie cut its 2026 adjusted EPS guidance to a midpoint of $13.86 due to $1.25 billion in acquired IPR&D and milestone expenses.
๐๏ธ The stock trades at a forward P/E of roughly 20x, which analysts consider a fair valuation for a high-quality compounder rather than a bargain.
๐ฌ The pipeline includes approximately 90 clinical programs, with two-thirds in mid- or late-stage development, offering potential upside if new indications succeed.
Bullish Signals
Dividend streak exceeds 50 years; payout hiked 5.5% to $1.73.
Skyrizi and Rinvoq generated over $8B Q2 revenue with double-digit growth.
Earnings inflecting from trough as new drugs compound post-Humira cliff.
Trades at forward P/E of roughly 20x for quality compounder.
Risk Factors
Dividend coverage weakened to 1.5x as payout rose to 65%.
Net debt load of $64B with 2.26x EBITDA leverage.
Apogee acquisition expected to trim 2026 EPS by $0.14.
Bullish Signals
AbbVie maintains an impressive 50+ year dividend growth streak, recently hiking the quarterly payout by 5.5% to $1.73.
Key immunology engines Skyrizi and Rinvoq combined generated over $8 billion in Q2 revenue with double-digit growth rates.
The company has successfully transitioned past the Humira cliff, with earnings inflecting from their trough as new drugs compound.
The stock trades at a forward P/E of roughly 20x, reflecting fair valuation for a quality compounder with high single-digit to low double-digit earnings growth.
Risk Factors
Free cash flow coverage of dividends has weakened to 1.5x as the payout ratio rose from 41% in fiscal 2022 to 65% in fiscal 2025.
The company carries a $64 billion net debt load with 2.26x EBITDA leverage, funded largely by acquisitions and high IPR&D expenses.
The pending acquisition of Apogee Therapeutics for $10.9 billion is expected to trim 2026 EPS by approximately $0.14.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)